PIONEERING
A NEW GENERATION OF MICROBIAL-INSPIRED THERAPEUTICS®

Axial Therapeutics has the bold vision that the gut microbiome harbors an untapped world of new drug targets and holds the promise to revolutionize medicine. We are harnessing groundbreaking microbiome science to develop innovative small molecule therapeutics against several diseases and disorders, including autism spectrum disorder, Parkinson’s disease, liver disease and oncology.

Clinical Study

Axial’s lead product candidate, AB-2004, is a gut-restricted molecular therapy being evaluated for the treatment of irritability associated with autism. We recently completed enrollment in a global, randomized, placebo-controlled Phase 2 clinical trial. Results from this trial are anticipated in Q1 2024.

At Axial, our Microbial-Inspired Therapeutics® Platform is at the forefront of scientific innovation in the gut microbiome and its impact on human health. With the goal of improving patients’ lives our initial focus of this broadly applicable platform is on the microbiome’s role in conditions such as Autism Spectrum Disorder (ASD) and Parkinson’s disease by leveraging our understanding of the microbiome’s connection to the nervous system.

LEARN MORE

OUR SCIENCE

Our scientific focus on the microbiome and its impact on human health represents a transformative therapeutic approach that has potential to treat diseases and disorders in ways never before possible.

LEARN MORE

OUR PIPELINE

We are advancing a pipeline of gut-targeted small molecule therapies in areas of significant unmet patient need including autism spectrum disorder and Parkinson’s disease, with early-stage programs in liver disease and oncology.

LEARN MORE